These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10176313)

  • 21. Price competition in pharmaceuticals - Evidence from 1303 Swedish markets.
    Granlund D; Bergman MA
    J Health Econ; 2018 Sep; 61():1-12. PubMed ID: 30007260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rx: higher prices.
    Kosterlitz J
    Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 32. The shifting functional balance of patents and drug regulation.
    Eisenberg RS
    Health Aff (Millwood); 2001; 20(5):119-35. PubMed ID: 11558697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug Reimbursement Regulation in 6 Peer Countries.
    Emanuel EJ; Zhang C; Glickman A; Gudbranson E; DiMagno SSP; Urwin JW
    JAMA Intern Med; 2020 Nov; 180(11):1510-1517. PubMed ID: 32986082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 36. The market for pharmaceuticals.
    Bergenheim K; Braun U
    Dev Health Econ Public Policy; 1998; 7():187-208. PubMed ID: 10538829
    [No Abstract]   [Full Text] [Related]  

  • 37. How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
    Beall RF; Hardcastle L; Clement F; Hollis A
    Health Policy; 2019 Dec; 123(12):1251-1258. PubMed ID: 31601457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry.
    McRae JJ; Tapon F
    J Health Econ; 1985 Mar; 4(1):43-61. PubMed ID: 10271145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law.
    Danieli D
    Health Econ Policy Law; 2021 Jan; 16(1):64-75. PubMed ID: 32434612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitigating regulatory impact: the case of partial price controls on metformin in India.
    Bhaskarabhatla A; Chatterjee C; Anurag P; Pennings E
    Health Policy Plan; 2017 Mar; 32(2):194-204. PubMed ID: 28207048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.